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Conclusions: Renal function was important predictive factor 
of 14 days mortality in cirrhotic patients with SBP. The patients 
with SBP and renal insufficiency should be treated more inten-
sively.
Keywords: Liver cirrhosis, Spontaneous bacterial peritonitis, 
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Background: Cirrhosis is a long-term consequence of chronic 
hepatic injury with fibrosis and no effective therapy except liver 
transplantation is currently available for decompensated cir-
rhosis. However, some practical limitations in liver transplan-
tation lead us to a need for new therapeutic paradigm in this 
field. Recent reports have shown that the mesenchymal stem 
cells (MSCs) have the plasticity to differentiate into some kinds 
of tissue cells and improve organ function. Hence, we investi-
gated the effect of direct inoculation of human bone marrow 
derived MSCs (BM-MSCs) in thioacetamide (TAA)-induced 
cirrhosis in a rat model.
Methods: Adult Sprague-Dawley rats were allocated into three 
groups (each group, n = 15) as follows: G1, shame; G2, TAA-
control; G3, TAA+BM-MSC. To induce cirrhosis, 200mg/kg 
TAA injection was done twice a week for 12weeks in G2 and 
G3. 2×106 cells of amplified human BM-MSCs were injected 
directly into the right liver lobe twice, at weeks 6 and 8 in G3. 
At 12 weeks, the effect of BM-MSCs on cirrhosis was analyzed 
histomorphologically using Laennec scores. α-Smooth muscle 
actin(α-SMA) expression by immunohistochemical staining, 
relative expression of collagen type 1, and transforming growth 
factor β (TGF-β) were also evaluated by real-time reverse tran-
scriptase-polymerase chain reaction.
Results: Laennec scores were 0, 5.4±0.7 and 3.7±1.06 in G1, 
G2 and G3, respectively. Histologically, BM-MSCs injected 
group (G3) showed significant suppression of hepatic fibrosis 
compared with TAA-control group (G2)(P<0.001). Expressions 
of α-SMA(%) were significantly lower in G3 than in G2 
(3.08±1.26 vs. 7.00±4.12, P<0.05). Also, the relative expression 
of collagen type 1 and TGF-β1 in RT-PCR were 0.64±0.24, 
2.06±0.51, 1.32±0.31 and 0.62±0.28, 5.89±3.05, 2.22±1.41 in 
G1, G2 and G3, respectively P<0.005).
Conclusions: Our results showed that BM-MSCs could atten-
uate liver fibrosis in rats with TAA-induced cirrhosis, raising 
the possibility for clinical use of BM-MSCs in the treatment of 
cirrhosis.
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Background: This study was conducted to investigate the effi-
cacy of probiotics administration in alleviating SIBO and intes-
tinal permeability in chronic liver disease.
Methods: Fifty three patients with chronic liver disease were 
randomized to receive either probiotics or placebo. After 4 
weeks, the changes in SIBO, intestinal permeability and clinical 
symptoms were examined and compared. The lactulose-based 
hydrogen breath test was conducted to identify SIBO. The in-
testinal permeability was assessed by comparing the absorb-
ability of lactulose and mannitol. The changes in digestive 
symptoms, composition of fecal bacteria, and liver function 
were also compared after four weeks of administration.
Results: The positive rate of SIBO was 26% in chronic liver 
disease patients. After four weeks later, in the probiotics group, 
24% of patients showed improvement of SIBO, but in placebo 
group, there was no patient whose SIBO was improved and 
16% showed aggravation of SIBO (P<0.05). The treatment 
group showed significant increase in the level of fecal B. lactis, 
L. rhamnosus, and L. acidophilus (P<0.05). Although probiotics 
also contained B. bifidum, B. longum, and S. thermophiles, the 
changes in the levels of B. bifidum, B. longum, and S. thermoph-
ilus were not significant. By contrast, there were no significant 
changes in the levels of the ingested bacteria in the placebo 
group. About half of treatment and 31.3% of placebo group re-
ported improvement in intestinal permeability, the difference 
between two groups was statistically insignificant (P=0.248). 
Improvement in abdominal pain of the probiotics and placebo 
group was 3.17±1.6 and 1.95±2.4 respectively (P=0.056) while 
improvement in gastrointestinal symptoms of the probiotics 
and placebo group was 3.35±1.7 and 2.05±2.3 respectively, sug-
gesting that digestive symptoms of the probiotics group im-
proved compared to placebo (P=0.047). 
Conclusions: 4 weeks probiotics administration in chronic 
liver disease patients was effective in alleviating SIBO and clini-
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cal symptoms but ineffective in improving intestinal permea-
bility and liver function.
Keywords: Probiotics, Small intestinal bacterial overgrowth, 
Chronic liver disease
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Background: Hepatologists and colonoscopists are often hesi-
tant to perform endoscopic polypectomy in patients with 
chronic liver disease (CLD), especially liver cirrhosis. We in-
vestigated the incidence of post-polypectomy bleeding (PPB) 
and factors which are related to PPB in these patients.
Methods: A total of 160 patients with CLD who underwent 
colonoscopic polypectomy between December 2005 and De-
cember 2012 were retrospectively reviewed. PPB was defined 
as melena, hematochezia, or hemoglobin concentration de-
creased by more than 2g/dl after polypectomy.
Results: The mean age of the study population (120 men, 
75%) was 61.1 years. Liver cirrhosis was identified in 84 
(52.5%) patients. Mean polyp size and number was 9.7 mm 
and 3.2, respectively. During the study period, PPB was ob-
served in 26 (16.9%) patients. All PPB was appropriately man-
aged without significant complications. Except mean polyp size 
(9.0 ± 5.3 mm in patients without PPB vs. 13.1 ± 7.6 mm in pa-
tients with PPB), baseline characteristics were not significantly 
different between the groups with and without PPB. On logistic 
regression analysis, only mean polyp size was significantly re-
lated to PPB (hazard ratio 1.009, 95% confidence interval 
1.032-1.170, P=0.003). The areas under the receiver operating 
characteristic curve of mean polyp size to predict PPB was 
0.638 (95% CI 0.508-0.767, P=0.025) in whole study popula-
tion and 0.703 (95% CI 0.575-0.831, P=0.002) in 136 (85.0%) 
patients with ≤5 polyps. The optimal cutoff mean polyp size to 
predict PPB was 11.8 mm (sensitivity 51.9%, specificity 84.6%, 
positive predictive value 89.4%, and negative predictive value 
41.2%).
Conclusions: Although the incidence of PPB in patients with 
CLD undergoing colonoscopic polypectomy was quite high, no 
significant PPB was observed. Only mean polyp size influenced 
the risk of PPB. Colonoscopic polypectomy can be performed 
cautiously in patients with CLD even with liver cirrhosis, be-
cause liver cirrhosis-related variables did not increase the risk 
of PPB.
Keywords: Post-polypectomy bleeding, Liver cirrhosis, Endoscop-
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Background: Hepatitis C virus (HCV) infection results in 
chronic liver diseases. The standard of care (SOC) of chronic 
hepatitis C is peginterferon alfa-2a/-2b with ribavirin. Howev-
er, not everyone with hepatitis C responds to drug therapy, and 
the drugs have side effects that can be difficult to tolerate. Gin-
seng has been one of the most commonly used herbal medi-
cines in Europe and North America. In this study, we investi-
gated the anti-HCV effect of ginsenosides which inhibit HCV 
NS3/4A activity. 
Methods and results: We conducted an in vitro NS3/4A as-
say to screen for ginsenosides showing inhibitory effect to 
HCV NS3/4A protease activity. Ginsenoside Rg3 caused nota-
ble dose-dependent reduction on in vitro HCV NS3/4A activity 
and did not show cell cytotoxicity in human hepatoma cells. 
Using Huh7.5.1 cells infected with JFH1 HCVcc, we further 
verified that ginsenoside Rg3 significantly suppresses HCV 
RNA replication by qRT-PCR and Western blot analyses. We 
also investigated the anti-apoptotic activity of ginsenosides in 
the cells undergoing HCV-induced apoptosis. We demonstrat-
ed that ginsenoside Rg3 effectively restored HCV-induced in-
crease in PARP cleavage and the expression of TNF-α mRNA, 
decline in NF-κ B activity, and cleavage in MAVS protein. Gin-
senoside Rg3 resulted in the decline of HCV-induced increase 
of antioxidant enzymes. Treatment of HCV-infected cells with 
ginsenoside Rg3 resulted in the inhibition of virus-induced 
